# OnCo record her2-low-and-trop2-adc-eligibility-tnbc (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/her2-low-and-trop2-adc-eligibility-tnbc/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "her2-low-and-trop2-adc-eligibility-tnbc" ;
  schema:name "HER2-low eligibility for trastuzumab deruxtecan, and TROP2 ADCs without a test (triple-negative disease)"@en ;
  schema:alternateName "HER2-low TNBC"@en, "HER2 0 versus 1+"@en, "T-DXd eligibility in triple-negative breast cancer"@en, "Sacituzumab govitecan eligibility"@en, "TROP2 testing not required"@en ;
  schema:description "Two antibody-drug conjugates reach triple-negative breast cancer by different rules. Trastuzumab deruxtecan needs the tumour to show a little HER2 (a score of 1+, or 2+ without gene amplification), so the pathologist's call between 0 and 1+ matters. Sacituzumab govitecan targets TROP2, which almost all breast cancers carry, and is given without any test."@en ;
  schema:url <https://onco.cc/terms/her2-low-and-trop2-adc-eligibility-tnbc/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Trastuzumab_deruxtecan> ;
  schema:citation <https://doi.org/10.1200/jco.2018.77.8738>, <https://doi.org/10.1200/jco.22.02864>, <https://doi.org/10.1056/nejmoa2203690>, <https://doi.org/10.1056/nejmoa2028485>, <https://www.nice.org.uk/guidance/ta819> ;
  onco:tag "breast", "tnbc" ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-metastatic/>, <https://onco.cc/cancers/her2-low-metastatic-breast-cancer/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:targets <https://onco.cc/targets/her2/>, <https://onco.cc/targets/trop2/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/sacituzumab-govitecan/> ;
  onco:terms <https://onco.cc/terms/her2-low/>, <https://onco.cc/terms/er-pr-negative-threshold/> ;
  onco:trials <https://onco.cc/trials/destiny-breast04/>, <https://onco.cc/trials/ascent/> .